This study states that Iliofemoral deep venous thrombosis (DVT) is associated with significant short- and long-term morbidity. Early thrombus removal is postulated to prevent the development of post-thrombotic syndrome by restoring unobstructed deep venous flow. Pharmacomechanical thrombolysis may be prohibitive in select patients with significant bleeding risks. The novel percutaneous thrombectomy device (ClotTriever; Inari Medical, Irvine, Calif) can minimize or even alleviate the need of thrombolytics while restoring venous patency. Patients who underwent percutaneous venous thrombectomy using the ClotTriever device for iliofemoral DVT between 2019 and 2020 were identified. Baseline demographics, risk factors, presenting symptoms, and perioperative outcomes were recorded. Technical success was defined as complete thrombus resolution based on venography or intravascular ultrasound. Major bleeding was defined as the need for blood transfusion, surgical reintervention, or intracranial hemorrhage. Ten patients were identified during the study period. Mean age was 62.8 years (range, 42-79 years). There were seven men and three women. All patients had iliofemoral DVT and four patients had clot extension into the vena cava. Four patients had one or more underlying risks factors for venous thrombosis and two patients had contraindications to the use of thrombolytics.